

# **Prophylactic Use of Esmolol in Patients Undergoing Coronary Artery Bypass Grafting**

Thesis submitted in partial fulfillment of the M.D degree in  
Anesthesiology

Presented by

**Soha Tarek El Said Kamal Talaat**

M.B.,B.CH., M.Sc. Anesthesiology

Under Supervision of

**Professor Dr. Nahed Effat Youssef**

Professor of Anesthesiology and Intensive Care  
Faculty of Medicine, Ain Shams University

**Professor Dr. Nabila Abd El Aziz Fahmy**

Professor of Anesthesiology and Intensive Care  
Faculty of Medicine, Ain Shams University

**Dr. Heba Bahaa El Din El Serwy**

Assistant Professor of Anesthesiology and Intensive Care  
Faculty of Medicine, Ain Shams University

**Faculty of Medicine  
Ain Shams University  
(2014)**

# الاستخدام الوقائي لعقار الازمولول في المرضى الذين يخضعون لعمليات استبدال الشرايين التاجية

رسالة مقدمة توطئة للحصول على درجة الدكتوراه في التخدير

مقدمة من

**الطبيبة/ سما طارق السيد جمال طاهر**

بكالوريوس الطب والجراحة-ماجستير التخدير-جامعة عين شمس

تحت إشراف

**الأستاذ الدكتور/ ناهد محمد يوسف**

أستاذ التخدير والرعاية المركزة  
كلية الطب-جامعة عين شمس

**الأستاذ الدكتور/ نبيلة محمد العزيز فهمي**

أستاذ التخدير والرعاية المركزة  
كلية الطب-جامعة عين شمس

**أستاذ مساعد / هبة بهاء الدين السروي**

أستاذ مساعد التخدير والرعاية المركزة  
كلية الطب-جامعة عين شمس

**كلية الطب**

**جامعة عين شمس**

**٢٠١٤**

يَرْفَعِ اللَّهُ الَّذِينَ آمَنُوا مِنْكُمْ وَالَّذِينَ أُوتُوا  
الْعِلْمَ دَرَجَاتٍ وَاللَّهُ بِمَا تَعْمَلُونَ خَبِيرٌ (١٥)

صدق الله العظيم



*First and foremost praise and thanks are given to ALLAH who provided me, in his unlimited generosity with the medical knowledge, and by his abundant aid this work has been done.*

*It is a great honor to express my sincere gratitude and deep appreciation to **Prof. Dr. Nahed Effat Youssef**, Professor of Anesthesia and Intensive Care, Faculty of Medicine, Ain Shams University. Who gave me the honor of working under her remarkable supervision that makes me really fortunate and who was kind to offer me much of her valuable time.*

*I would like also to express my sincere gratitude and deep appreciation to **Prof. Dr. Nabila Abd El Aziz Fahmy**, Professor of Anesthesia and Intensive Care, Faculty of Medicine, Ain Shams University. Who gave me the honor of working under her supervision, for her careful and great support in this thesis and valuable and precious experience.*

*I would like also to express my deep obligation to **Dr. Heba Bahaa El Din El Serwy**, Assistant professor of Anesthesia and Intensive Care, Faculty of Medicine, Ain Shams University. For supervising the whole work, reading and criticizing the manuscript. I will never forget his unlimited help, continuous support and kind encouragement.*

*Finally I cannot fully express by any words my deep gratitude to my parents, my husband and my friends, whom I owe a lot and dedicate this work, hoping it will help in improving the outcome of cardiac surgical patients.*

# Contents

<b><i>Acknowledgment</i></b>	I
<b><i>Abbreviations</i></b>	
<b><i>List of Figures</i></b>	
<b><i>List of tables</i></b>	
<b><i>Introduction and Aim of work</i></b>	
<b><i>Review of literature</i></b>	
<b><i>Chapter 1</i></b>	1
<b><i>Chapter 2</i></b>	24
<b><i>Chapter 3</i></b>	47
<b><i>Chapter 4</i></b>	67
<b><i>Patient and methods</i></b>	73
<b><i>Results</i></b>	85
<b><i>Discussion</i></b>	103
<b><i>Summary</i></b>	123
<b><i>Conclusion &amp; recommendations</i></b>	125
<b><i>References</i></b>	126
<b><i>Arabic Summary</i></b>	

## **Abbreviations**

ABG: Arterial blood gases

ACCF: American College of Cardiology Foundation

ACT: Activated clotting time

AHA: American Heart Association

ASA: American Society of Anesthesiologists

ASA: American stroke association

CABG: Coronary artery bypass graft

CARE score: cardiac anesthesia risk evaluation

CPB: Cardiopulmonary bypass

CVA: cerebrovascular accident

CVP: central venous pressure

DM: Diabetes mellitus

EACA:  $\epsilon$ -aminocaproic acid

ECG: Electrocardiography

EF: Ejection Fraction

EuroSCORE: European System Cardiac Operative Risk Evaluation

Hb: hemoglobin

HbA1C: glycosylated hemoglobin A1c

IABP: Intra aortic balloon pump

ITA: Internal thoracic artery

L/min/m<sup>2</sup>: Litre/minute/m<sup>2</sup> of body surface area

LAD: Left anterior descending

LBBB: Left Bundle Branch Block

LV: left ventricle

LVEF: Left ventricular ejection fraction

MAP: mean arterial pressure

MI: myocardial infarction

MRSA: methicillin-resistant staph aureus

MVO<sub>2</sub>: Myocardial Oxygen Consumption

ng/kg/min: nannogram/kilogram/minute

NIRS: near-infrared spectroscopy

NMBA: Neuromuscular Blocking Agents

NSTEMI: Non-ST segment elevation myocardial infarction

PCI: Percutaneous Coronary Intervention

POAF: Postoperative atrial fibrillation

POCD: postoperative cognitive dysfunction

PRBCs: packed red blood cells

RCA: Right coronary artery

STEMI: ST-elevated myocardial infarction

STS: society of thoracic surgeons

TA: Tranexamic acid

TEA: Thoracic Epidural Anesthesia

UA: unstable angina

VF: ventricular fibrillation

VT: ventricular tachycardia

$\alpha$ : Alpha

$\beta$ : Beta



## List of Figures

<b>S</b>	<b>NAME</b>	<b>P</b>
1	Logistic EuroSCORE equation. Quoted from	10
2	Cardiopulmonary bypass component.	25
3	A modern hollow-fibre membrane counterpart.	27
4	Structural Formula of Major Beta-Blockers Used in Anesthesiology.	48
5	Structure of Esmolol.	68
6	Heart Rate.	86
7	Mean arterial pressure (MAP) before and after CPB.	87
8	Mean arterial blood pressure (MAP) during CPB.	88
9	Pump flow on CPB.	89
10	Central venous pressure.	90
11	ETCO <sub>2</sub> .	91
12	Arterial Carbon Dioxide Tension(PCO <sub>2</sub> ).	92
13	Arterial Oxygen Tension (PO <sub>2</sub> ).	93
14	SpO <sub>2</sub> .	94
15	Temperature.	95
16	Serum potassium (K).	95
17	Serum arterial lactate.	96
18	Myocardial Ischemic Marker CK (IU/L) measured at baseline and 12 hours postoperative in the control and Esmolol groups.	97
19	Troponin I serum levels (ng/ml) at baseline and at 12 hours postoperative.	98
20	Troponin T levels (ng/L) at baseline and at 12 hours postoperative in the control and esmolol groups.	99
21	Ejection fraction taken pre and postoperative in the control and esmolol groups.	100
22	Postoperative variables.	101
23	Postoperative complications.	102

## List of tables

S	Name	P
1.	<b>2011 ACCF/AHA Guideline for CABG</b>	4
2.	<b>The Parsonnet additive risk stratification model for cardiac surgery.</b>	9
3.	<b>EuroSCORE—The European System for Cardiac Operative Risk Evaluation additive risk stratification model.</b>	12
4.	<b>Independent Variables Associated with Mortality After Isolated Coronary Artery Bypass Graft (CABG) Surgery.</b>	14
5.	<b>Variables Associated with Development of a Major Complication After Isolated Coronary Artery Bypass Graft Surgery (CABG)</b>	15
6.	<b>The Cardiac Anaesthesia Risk Evaluation (CARE) Score</b>	21
7.	<b>Complications of CPB.</b>	30
8.	<b>Evidence-based strategies for cerebral protection during cardiac surgery</b>	35
9.	<b>Current recommendations of the STS regarding blood glucose management during adult cardiac surgery</b>	36
10.	<b>Arterial Pressure Management.</b>	40
11.	<b>Factors Determining Minimal Safe Pump Flow During Cardiopulmonary Bypass.</b>	42
12.	<b>O<sub>2</sub> delivery equations</b>	43
13.	<b>Major Adrenergic Receptors.</b>	50
14.	<b>Major Beta-Blockers and their Specific Properties.</b>	51

15.	<b>Beta-Blockers Major Pharmacokinetic Parameters.</b>	54
16.	<b>Intravenous Beta-Blockers.</b>	56
17.	<b>showing Demographic &amp; Pre-study data.</b>	85
18.	<b>Heart Rate.</b>	86
19.	<b>Mean arterial pressure (MAP) before and after CPB.</b>	87
20.	<b>Mean arterial blood pressure (MAP) during CPB.</b>	88
21.	<b>Pump flow on CPB.</b>	89
22.	<b>Central Venous Pressure.</b>	90
23.	<b>ETCO<sub>2</sub>.</b>	91
24.	<b>Arterial Carbon Dioxide Tension (PCO<sub>2</sub>).</b>	92
25.	<b>Arterial Oxygen Tension (PO<sub>2</sub>).</b>	93
26.	<b>SpO<sub>2</sub>.</b>	93
27.	<b>Temperature.</b>	94
28.	<b>Serum potassium (K).</b>	95
29.	<b>Serum arterial lactate.</b>	96
30.	<b>Serum creatine kinase.</b>	97
31.	<b>Serum CK-MB.</b>	97
32.	<b>Serum Troponin I.</b>	98
33.	<b>Serum Troponin T.</b>	99
34.	<b>showing echocardiography (EF).</b>	100
35.	<b>Postoperative variables.</b>	101
36.	<b>Postoperative complications.</b>	102

## Introduction

During the past two decades,  $\beta$ -adrenergic blockade has been demonstrated to improve acute outcomes and long-term prognosis in ischemic heart disease (*Ryan et al, 1999*).  $\beta$ -blocker therapy has also been demonstrated to reduce perioperative events among high-risk patients undergoing major non-cardiac and vascular surgery (*Weisbauer et. al., 2007*).

Also, the administration of  $\beta$ -adrenergic antagonists is known to attenuate myocardial ischemia-reperfusion injury during cardiac surgery. However,  $\beta$ -adrenergic antagonists have been avoided during cardiopulmonary bypass (CPB) because of concern that the negative inotropic effects induced may make it difficult to terminate CPB (*Scorsin et. al., 2003*).

Esmolol is an ultra-short acting  $\beta$ -blocker which is rapidly metabolized in the blood by red blood cell esterase with elimination half-life of only 9 minutes ( *Quon & Stimpfli, 1985*). All these properties make this  $\beta$ -blocker the first choice drug in critical patients in whom possible side effects such as cardiac failure, hypotension, or bradycardia make a rapid and immediate interruption of drug administration necessary and the concern of difficult weaning from CPB is not an issue anymore (*Cork, et al., 1995*).

## **Aim of the Work**

The aim of this work is to compare the clinical and biochemical effects of placebo and esmolol infused intraoperatively following induction in patients undergoing isolated coronary artery bypass graft (CABG) surgery and whether it is correlated with more improvement in postoperative morbidity and mortality.

# Coronary Artery Bypass Grafting (CABG)

## History of Coronary Artery Bypass Grafting

Indirect methods to restore blood supply to the ischemic myocardium were pioneered by **Claude Beck**, who reported in 1935 on the placement of a pedicled pectoralis muscle flap on the abraded pericardium (*Beck, 1935*). In 1951 **Vineberg** described direct implantation of the internal thoracic artery (ITA) into the myocardium (*Vineberg & Niloff, 1950; Vineberg A, Miller, 1951*), and **Sen** described "myocardial acupuncture" in 1968 (*Sen et al., 1968*).

Gibbon's development of the cardiopulmonary bypass machine and its successful clinical application by **Kirklin** at the Mayo Clinic and **Lillehei** at the University of Minnesota (*Gibbon, 1954; Lillehei et al., 1955*); made direct coronary revascularization technically feasible. Bailey in 1957 reported the first successful coronary endarterectomy, and in 1958 **Longmire** reported a mammary-to-coronary anastomosis performed after a surgical misadventure with a coronary endarterectomy (*Bailey et al., 1957*).

**Goetz** in 1960 performed the first successful planned coronary artery bypass operation, employing a metal cannula to connect the right ITA to the right coronary artery (RCA), with angiographic patency confirmed 2 weeks after operation (*Goetz et al., 1961*). The first reported use of a saphenous vein aorto-coronary bypass was reported by **Sabiston** in 1962; however, the postoperative death of the patient dissuaded

repetition of the procedure (*Sabiston, 1963a; Sabiston, 1963b*). The Russian surgeon **Kolessov** is credited with the first successful planned sutured internal mammary-to-coronary anastomosis in 1964 (*Kolessov, 1966; Kolessov, 1967*). **Garrett and DeBakey** reported a 7-year follow-up of a bypass with venous conduit performed also in 1964 (*Garrett et al., 1973*).

It was, however, the development of coronary angiography by **Mason Sones** at the Cleveland Clinic in 1957 that opened the door to the elective treatment of coronary atherosclerosis by means of direct revascularization (*Sones & Shirey, 1968*). Initial studies by **Rene Favaloro** and **Donald B. Effler** with venous and arterial conduits, and their systematic application of these techniques to treat clinical events associated with stenotic lesions of the coronary arteries, culminated in the first large series of aorto-coronary grafts with venous conduits reported in 1968 (*Favaloro, 1970*). Simultaneously **Dudley Johnson** of Milwaukee published a series of 301 patients undergoing coronary bypass with venous conduits in 1969 (*Johnson et al., 1969*). The success of these techniques was soon demonstrated in larger series, initiating the modern era of coronary artery surgery (*Favaloro et al., 1970*).

## **Indications for CABG**

CABG is performed for both symptomatic and prognostic reasons. Indications for CABG have been classified by the American College of Cardiology (ACC) and the American Heart Association (AHA) according to the level of evidence supporting the usefulness and efficacy of the procedure as shown in table 1 (*Eagle et al., 2004; Hillis et al., 2011*):